Related Experiment Videos
Valproate-induced thrombocytopenia: a prospective monotherapy study
Wassim Nasreddine1, Ahmad Beydoun
1Beirut Governmental University Hospital, Beirut, Lebanon.
Epilepsia
|November 23, 2007
Summary
Valproate (VPA) increases the risk of thrombocytopenia, especially in women. Higher VPA plasma levels correlate with lower platelet counts, necessitating careful monitoring in epilepsy patients.
Area of Science:
- Neurology
- Pharmacology
- Hematology
Background:
- Valproate (VPA) is an antiepileptic drug with variable reported rates of induced thrombocytopenia.
- Methodological differences in prior studies contribute to the wide range of reported VPA-induced thrombocytopenia frequencies.
Purpose of the Study:
- To determine the relationship between trough valproate plasma levels and platelet counts.
- To identify risk factors associated with the development of valproate-induced thrombocytopenia.
Main Methods:
- A double-blind, multicenter, concentration-response trial involving 265 patients with refractory partial epilepsy.
- Analysis of 851 valproate levels and platelet counts, using bivariate correlations, stepwise regression, and logistic regression.
Main Results:
- 17.7% of patients experienced thrombocytopenia (platelet count ≤ 100,000/microl) during the 24-week trial.
- A significant negative correlation was observed between valproate levels and platelet counts.
- Female gender and lower baseline platelet counts were identified as risk factors; increased thrombocytopenia risk was noted at VPA levels >100 µg/mL (women) and >130 µg/mL (men).
Conclusions:
- A causal relationship exists between elevated valproate plasma levels and reduced platelet counts.
- Female gender and lower baseline platelet counts are significant risk factors for VPA-induced thrombocytopenia.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...